Onxeo SA
PAR:ALONX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Onxeo SA
Other Current Assets
Onxeo SA
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Onxeo SA
PAR:ALONX
|
Other Current Assets
€288k
|
CAGR 3-Years
13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Current Assets
€34.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Assets
€2.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Other Current Assets
€2.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Current Assets
$2.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Abivax SA
PAR:ABVX
|
Other Current Assets
€3.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
58%
|
CAGR 10-Years
39%
|
|
Onxeo SA
Glance View
Onxeo SA is a is a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2005-07-12. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
See Also
What is Onxeo SA's Other Current Assets?
Other Current Assets
288k
EUR
Based on the financial report for Dec 31, 2022, Onxeo SA's Other Current Assets amounts to 288k EUR.
What is Onxeo SA's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-10%
Over the last year, the Other Current Assets growth was -80%. The average annual Other Current Assets growth rates for Onxeo SA have been 13% over the past three years , -10% over the past five years .
